Literature DB >> 29388201

Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder.

Ahmed T Ahmed1, Richard Weinshilboum2, Mark A Frye1.   

Abstract

Antidepressants have reduced the symptom burden for many Major Depressive Disorder (MDD) patients, but drug-related side effects and treatment resistance continue to present major challenges. Pharmacogenomics represents one approach to enhance antidepressant efficacy and avoid adverse reactions, but concerns remain with regard to the overall "value equation," and several barriers must be overcome to achieve the full potential of MDD pharmacogenomics.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29388201      PMCID： PMC6380658          DOI： 10.1002/cpt.1009

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  4 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.

Authors:  Yuan Ji; Jennifer M Skierka; Joseph H Blommel; Brenda E Moore; Douglas L VanCuyk; Jamie K Bruflat; Lisa M Peterson; Tamra L Veldhuizen; Numrah Fadra; Sandra E Peterson; Susan A Lagerstedt; Laura J Train; Linnea M Baudhuin; Eric W Klee; Matthew J Ferber; Suzette J Bielinski; Pedro J Caraballo; Richard M Weinshilboum; John L Black
Journal:  J Mol Diagn       Date:  2016-03-03       Impact factor: 5.568

3.  Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality.

Authors:  Jennifer L St Sauver; Suzette J Bielinski; Janet E Olson; Elizabeth J Bell; Michaela E Mc Gree; Debra J Jacobson; Jennifer B McCormick; Pedro J Caraballo; Paul Y Takahashi; Veronique L Roger; Carolyn R Rohrer Vitek
Journal:  Am J Med       Date:  2016-05-05       Impact factor: 4.965

4.  TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.

Authors:  M Gupta; D Neavin; D Liu; J Biernacka; D Hall-Flavin; W V Bobo; M A Frye; M Skime; G D Jenkins; A Batzler; K Kalari; W Matson; S S Bhasin; H Zhu; T Mushiroda; Y Nakamura; M Kubo; L Wang; R Kaddurah-Daouk; R M Weinshilboum
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992
  4 in total
  2 in total

Review 1.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

Review 2.  Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection.

Authors:  Alfredo B Cuéllar-Barboza; Susan L McElroy; Marin Veldic; Balwinder Singh; Simon Kung; Francisco Romo-Nava; Nicolas A Nunez; Alejandra Cabello-Arreola; Brandon J Coombes; Miguel Prieto; Hannah K Betcher; Katherine M Moore; Stacey J Winham; Joanna M Biernacka; Mark A Frye
Journal:  Int J Bipolar Disord       Date:  2020-07-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.